Do All Abdominal Neuroendocrine Tumors Require Extended Postoperative VTE Prophylaxis? A NSQIP Analysis.


Journal

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084

Informations de publication

Date de publication:
04 2019
Historique:
received: 16 09 2018
accepted: 27 11 2018
pubmed: 24 1 2019
medline: 11 7 2020
entrez: 24 1 2019
Statut: ppublish

Résumé

Venous thromboembolism (VTE) occurs at high incidence in abdominal cancer surgery; therefore, a 4-week postoperative VTE prophylaxis is advocated. However, most patients with neuroendocrine tumors (NETs) have more favorable prognoses. This study aimed to determine the incidence of VTE in patients with abdominal NETs, compare these rates to other abdominal malignancies, and identify VTE risk factors. The ACS-NSQIP database was queried to identify patients with abdominal NETs and other abdominal malignancies who underwent surgery from 2008 to 2015. A 30-day postoperative VTE incidence for each group was compared. Univariable and multivariable analyses were used to identify VTE risk factors. Of the 7226 operations for patients with benign (2154) and malignant (5072) abdominal NETs, 144 patients experienced a VTE without significant differences between groups. Subgroup analysis revealed a spectrum of VTE rates. Compared to VTE rates of other abdominal malignancies, patients with benign (1.1% vs. 2.4%, p < 0.001) or malignant (1.7% vs. 2.4%, p < 0.001) non-pancreatic abdominal NETs had significantly lower rates, malignant pancreatic NETs (PNETs) (3.4% vs. 2.4%, p = 0.03) had significantly higher rates, and benign PNETs (3.2% vs. 2.4%, p = 0.21) had comparable rates. Multivariable analysis identified pre-operative albumin (p < 0.001), bleeding disorders (p < 0.001), operative time (p < 0.001), and having a PNET (p = 0.04) as risk factors for VTE in abdominal NET patients. Routine extended VTE prophylaxis after surgery may be necessary in PNETs, but probably unnecessary in other abdominal NETs. However, clinicians should use risk factors identified in this study when considering to forego extended VTE prophylaxis in NET patients.

Sections du résumé

BACKGROUND
Venous thromboembolism (VTE) occurs at high incidence in abdominal cancer surgery; therefore, a 4-week postoperative VTE prophylaxis is advocated. However, most patients with neuroendocrine tumors (NETs) have more favorable prognoses. This study aimed to determine the incidence of VTE in patients with abdominal NETs, compare these rates to other abdominal malignancies, and identify VTE risk factors.
METHODS
The ACS-NSQIP database was queried to identify patients with abdominal NETs and other abdominal malignancies who underwent surgery from 2008 to 2015. A 30-day postoperative VTE incidence for each group was compared. Univariable and multivariable analyses were used to identify VTE risk factors.
RESULTS
Of the 7226 operations for patients with benign (2154) and malignant (5072) abdominal NETs, 144 patients experienced a VTE without significant differences between groups. Subgroup analysis revealed a spectrum of VTE rates. Compared to VTE rates of other abdominal malignancies, patients with benign (1.1% vs. 2.4%, p < 0.001) or malignant (1.7% vs. 2.4%, p < 0.001) non-pancreatic abdominal NETs had significantly lower rates, malignant pancreatic NETs (PNETs) (3.4% vs. 2.4%, p = 0.03) had significantly higher rates, and benign PNETs (3.2% vs. 2.4%, p = 0.21) had comparable rates. Multivariable analysis identified pre-operative albumin (p < 0.001), bleeding disorders (p < 0.001), operative time (p < 0.001), and having a PNET (p = 0.04) as risk factors for VTE in abdominal NET patients.
CONCLUSION
Routine extended VTE prophylaxis after surgery may be necessary in PNETs, but probably unnecessary in other abdominal NETs. However, clinicians should use risk factors identified in this study when considering to forego extended VTE prophylaxis in NET patients.

Identifiants

pubmed: 30671795
doi: 10.1007/s11605-018-04075-y
pii: 10.1007/s11605-018-04075-y
doi:

Substances chimiques

Anticoagulants 0
Serum Albumin 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

788-793

Références

N Engl J Med. 2002 Mar 28;346(13):975-80
pubmed: 11919306
Chest. 2004 Sep;126(3 Suppl):338S-400S
pubmed: 15383478
J Thromb Haemost. 2006 Nov;4(11):2384-90
pubmed: 16881934
J Am Coll Surg. 2007 Jun;204(6):1211-21
pubmed: 17544079
J Clin Oncol. 2007 Dec 1;25(34):5490-505
pubmed: 17968019
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Ann Surg. 2009 Jan;249(1):63-71
pubmed: 19106677
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004318
pubmed: 19160234
J Thromb Thrombolysis. 2009 Nov;28(4):458-64
pubmed: 19479199
Ann Surg. 2010 Feb;251(2):344-50
pubmed: 19779324
Am J Surg. 2010 Jan;199(1 Suppl):S3-10
pubmed: 20103082
Chest. 2012 Feb;141(2 Suppl):7S-47S
pubmed: 22315257
Chest. 2012 Feb;141(2 Suppl):e227S-e277S
pubmed: 22315263
Surgery. 2012 Oct;152(4):528-34; discussion 534-6
pubmed: 23021132
HPB (Oxford). 2013 Oct;15(10):773-80
pubmed: 23869577
HPB (Oxford). 2014 Apr;16(4):373-83
pubmed: 23869628
J Natl Compr Canc Netw. 2013 Nov;11(11):1402-29
pubmed: 24225973
Phlebology. 2015 Jun;30(5):350-6
pubmed: 24681524
Ann Surg. 2015 Jun;261(6):1160-6
pubmed: 24983992
JAMA Surg. 2015 Feb;150(2):110-7
pubmed: 25472485
Ann Surg Oncol. 2016 May;23(5):1422-30
pubmed: 26887853
J Surg Res. 2016 Oct;205(2):279-285
pubmed: 27664873
HPB (Oxford). 2018 Jul;20(7):621-630
pubmed: 29472105

Auteurs

Nicholas J Skertich (NJ)

Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, 1750 W. Harrison Street, Jelke Building Suite 785, Chicago, IL, 60612, USA.

Justin Gerard (J)

Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, 1750 W. Harrison Street, Jelke Building Suite 785, Chicago, IL, 60612, USA.

Jennifer Poirier (J)

Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, 1750 W. Harrison Street, Jelke Building Suite 785, Chicago, IL, 60612, USA.

Martin Hertl (M)

Department of Surgery, Division of Transplant Surgery, Rush University Medical Center, Chicago, IL, USA.

Sam G Pappas (SG)

Department of Surgery, Division of Surgical Oncology, Rush University Medical Center, 1750 W. Harrison Street, Jelke Building Suite 785, Chicago, IL, 60612, USA.

Erik Schadde (E)

Department of Surgery, Division of Transplant Surgery, Rush University Medical Center, Chicago, IL, USA.

Xavier M Keutgen (XM)

Department of Surgery, Division of General Surgery and Surgical Oncology, Endocrine Research Program, The University of Chicago Medicine and Biological Sciences Division, 5841 S. Maryland Ave, Chicago, IL, 60637, USA. xkeutgen@surgery.bsd.uchicago.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH